Cost-effectiveness of programmed death ligand-1 (PD-L1) blockade in first-line for metastatic gastric/gastroesophageal junction cancer
-
Published:2022-11
Issue:
Volume:175
Page:193-195
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Giuliani JacopoORCID,
Mantoan Beatrice,
Bonetti Andrea
Subject
Cancer Research,Oncology
Reference10 articles.
1. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial;Janjigian;Lancet,2021
2. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial;Shitara;JAMA Oncol,2020
3. The pharmacological costs of first-line therapies in unselected patients with advanced colorectal cancer: a review of published phase III trials;Giuliani;Clin Colorectal Cancer,2016
4. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS);Cherny;Ann Oncol,2015
5. Which grade is of clinical benefit in the randomised controlled trials? The example of 54th American Society of Clinical Oncology annual meeting, 2018;Giuliani;Eur J Cancer,2018
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献